Patient-reported quality of life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Interim results of the TALLISUR study.

Meinolf Karthaus(Evangelisches Krankenhaus Bielefeld), Henning Pelz(Praxis für Hämatologie und Onkologie), Volker Heinemann(LMU Klinikum), Rolf Mahlberg(Klinikum Mutterhaus der Borromäerinnen), Manfred Welslau(Praxis für Hämatologie und Onkologie), Florian Kaiser(University of Applied Sciences Landshut), Jorge Riera Knorrenschild(Philipps University of Marburg), Albrecht Kretzschmar(Roche (Switzerland)), Stefan Fuxius(Praxis für Hämatologie und Onkologie)
Journal of Clinical Oncology
May 20, 2021
10.1200/jco.2021.39.15_suppl.3526
Cited by 0

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer
|JAMA Oncology|2016|722
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
|European Journal of Cancer|2011|615